The germline mutation not only informs screening for secondary cancers and testing in relatives, BRCA2 mutations may also be associated with a worse prognosis [65,66,67,68,69] and confer sensitivity to platinum-based chemotherapy [70] and PARP-inhibitors [23,53]. Here, BRCA2 is linked to cancer.